Vor Biopharma Inc.
No enriched coverage for $VOR in the last 7 days.
No SEC Form 4 filings for $VOR in the last 30 days.
Vor Biopharma Inc. (NASDAQ:VOR) experienced a 17.3% decrease in short interest in April, with the total short interest reaching 4,706,707 shares as of April 15th. This represents 9.7% of the company's float, with a days-to-cover ratio of 3.5 days. The stock was trading up 5.6% at midday, reaching $14.81, while analysts maintain a "Moderate Buy" consensus with an average price target of $50.56.
RA Capital Healthcare Fund LP sold 630,374 shares of Vor Biopharma Inc. (NASDAQ:VOR) common stock for approximately $10.17 million across two transactions in April 2026. Following these sales, RA Capital Healthcare Fund LP retains 2,567,245 shares of Vor Biopharma. The company has recently shifted its focus to autoimmune therapies and initiated a global Phase 3 trial for Sjögren’s disease, while analysts have adjusted price targets but largely maintain positive ratings due to promising drug potential.
RA Capital Management and its affiliated funds have reported a slight reduction in their beneficial ownership of Vor Biopharma (VOR) common stock. Despite recent open-market sales, RA Capital still maintains a significant 19.9% stake in the company, which includes a mix of common shares, common stock warrants, and pre-funded warrants. The firm's ownership is subject to a "Beneficial Ownership Blocker" that limits its exercise of pre-funded warrants to prevent exceeding 19.99% ownership.
